Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant hiv-1-infected patients: a randomized open-label trial

Clinical Infectious Diseases

Volumn 49, Issue 8, 2009, Pages 1259-1267

  De Castro, Nathalie ^a,g   Braun, Joséphine ^h   Charreau, Isabelle ^h   Pialoux, Gilles ^b   Cotte, Laurent ⁱ   Katlama, Christine ^c   Raffi, François ^j   Weiss, Laurence ^d   Meynard, Jean Luc ^e   Yazdanpanah, Yazdan ^k   Delaugerre, Constance ^f   Madelaine Chambrin, Isabelle ^g   Aboulker, Jean Pierre ^h   Molina, Jean Michel ^a,g  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL TENON   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f Virology And   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h INSERM   (France)

ⁱ HÔTEL DIEU   (France)

^j HÔTEL DIEU   (France)

^k NONE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; RALTEGRAVIR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPASEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PYRROLIDINONES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70349902494     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605674     Document Type: Article

References (21)

1. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195 (Pubitemid 36618129)
2. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor for drug-resistant HIV Infection in North and South America. N Engl J Med 2003;348:2175-2185 (Pubitemid 36618128)
3. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy over 48 weeks in heavily treatment experienced HIV-1 -infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-412 (Pubitemid 41669173)
4. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretro virais in treatmentexperienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40:413-421 (Pubitemid 41669174)
5. Bonjoch A, Negredo E, Puig J, et al. Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide. AIDS 2006;20:1896-1898 (Pubitemid 44358911)
6. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46:125-133 (Pubitemid 47482607)
7. Grinsztejn, B, Nguyen B-Y, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet 2007;369:1261-1269 (Pubitemid 46553846)
8. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354
9. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365
10. Harris M, Larsen G, Montaner JSG. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008;22:1224-1226
11. Towner W, Klein D, Follansbee S, Yu K, Kerrigan H, Horberg M. Pilot study of switching enfuvirtide to raltegravir in HIV-1 positive patients well controlled on an enfuvirtide based regimen [abstract TUPE0115]. In: Program and abstracts of the XVII International AIDS Conference (Mexico City, Mexico). 2008.
12. Talbot A, Marcotte S, Lalonde RG, et al. Retrospective analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 12 weeks in a Montreal cohort [abstract TUPE0112], In: Program and abstracts of the XVII International AIDS Conference (Mexico City, Mexico). 2008.
13. Descamps D, Delaugerre C, Masquelier B, et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006;78:153-160 (Pubitemid 43132558)
14. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145
15. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19 1993.
16. Raffi F, Katlama C, Saag M, et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006;42:870-877 (Pubitemid 43363947)
17. Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ ritonavir based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologie efficacy at week 24 [abstract 70aLB]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal, Canada). 2009.
18. Macías J, Orihuela F, Rivero A, et al. Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. J Antimicrob Chemother 2009;63:178-183
19. Wenning LA, Hanley W, Stone J, et al. Effect of tipranavir+ ritonavir on pharmacokinetics of MK-0518 [abstract A374], In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). 2006.
20. de Requena DG, Calcagno A, Bonora S, et al. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS 2006; 20:1977-1979 (Pubitemid 44427617)
21. Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007;21:1977-1980 (Pubitemid 47333873)